Skip to main content

Table 3 Kaplan-Meier rate estimates: proportions of patients achieving first PASI 50, 75, and 90, by treatment group

From: Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

PASI Response

% of Patients (95 % CI)

Week 0–8

Week 0–12

Week 0–24

QW/QW n = 86

BIW/QW n = 84

QW/QW n = 86

BIW/QW n = 84

QW/QW n = 86

BIW/QW n = 84

PASI 50

59.5\ (49.3, 70.0)

79.5 (70.3, 87.4)

75.5 (65.8, 84.1)

92.8 (85.9, 97.0)

90.5 (82.8, 95.6)

98.8 (94.2, 99.9)

PASI 75

27.4 (19.1, 38.3)

45.8 (35.8, 57.1)

41.9 (32.2, 53.2)

68.7 (58.6, 78.3)

72.5 (62.5, 81.6)

95.2 (89.1, 98.4)

PASI 90

7.2 (3.3, 15.2)

13.3 (7.6, 22.7)

15.6 (9.4, 25.3)

32.5 (23.6, 43.7)

47.7 (37.5, 59.1)

61.5 (51.2, 71.8)

  1. BIW twice weekly, CI confidence interval, PASI Psoriasis Area and Severity Index, QW once weekly